Overview

Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study will examine whether lansoprazole (Prevacid) and dietary control versus dietary control alone will improve pediatric hoarseness symptoms.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Kansas
University of Kansas Medical Center
Collaborator:
TAP Pharmaceutical Products Inc.
Treatments:
Dexlansoprazole
Lansoprazole
Proton Pump Inhibitors
Criteria
Inclusion Criteria:

1. Healthy children with a diagnosis of dysphonia age 3-18 years.

2. Dysphonia must be present for at least one month duration.

3. May have vocal cord nodules present.

4. Pre-enrollment flexible fiberoptic laryngoscopy must not show any potentially
life-threatening cause, including but not limited to laryngeal papillomatosis,
congenital glottic webs, vocal cord paralysis, or benign and malignant neoplasms.

5. Must be able to cooperate with recording of voice for analysis(3 seconds of sustained
vowel).

6. Caregiver must be able to read, write, and understand English.

7. Patient with history of diagnosed asthma must have their asthma well controlled and
treated at the time of enrollment for study.

Exclusion Criteria:

1. Dysphonia must not be due to a potentially life-threatening cause, such as laryngeal
papillomatosis, congenital glottic webs, vocal cord paralysis, or benign and malignant
neoplasms. This will be determined by visualization with flexible fiberoptic
laryngoscopy.

2. Dysphonia must not be due to an acute upper respiratory infection.

3. Must not have been treated with proton pump inhibitor medication in the past 12
months.

4. Inability of child to cooperate with recording of voice for analysis.

5. Inability of caregiver to read, write, and understand English.

6. Mental retardation, cognitive impairment, or developmental delay.

7. History of allergic reaction of any kind to lansoprazole or any other proton pump
inhibitor.